CONFERENCE ROUNDUP

Study: Brolucizumab use for nAMD poses challenges

According to a recent study presented at ARVO 2021, intravitreal brolucizumab use (IVB; Beovu, Novartis)  was significant for risks versus intravitreal aflibercept (IVA; Eylea, Regeneron Pharmaceuticals, Inc.) in eyes with prior anti-VEGF. With $883 per event added to the marketed q12W cost, IVB is still cost efficient by $3237 versus...